血管内皮生长因子信号通路抑制剂相关高血压研究进展  

Progress of research on hypertension related to inhibitors of vascular endothelial growth factor signaling pathway

作　　者：董志超[1] 吕海辰[1] DONG Zhichao;LYU Haichen(Department of Cardiology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China)

机构地区：[1]大连医科大学附属第一医院心内科,辽宁大连116011

出　　处：《大连医科大学学报》2022年第1期1-8,共8页Journal of Dalian Medical University

基　　金：国家自然科学基金面上项目(82170252);国家自然科学基金青年项目(81700245);辽宁省自然科学基金面上项目(2019-MS-081)。

摘　　要：抗肿瘤治疗领域的不断进步,使得肿瘤患者得以长期生存,但其诱导的心血管并发症也愈发突出。高血压是血管内皮生长因子信号通路抑制剂最常见的副反应,由此引发严重的心血管并发症,对肿瘤患者的预后影响巨大。然而,现有指南对此类高血压的机制、发病特点、管理及治疗阐述甚少。本文系统地回顾了血管内皮生长因子信号通路抑制剂相关高血压的文献,供临床医师参考。With the development of anti-cancer therapy, life span of cancer patients has been extending. Cardiovascular complications related to anti-cancer therapy become an important health threat to cancer survivors. As the most common side effect of vascular endothelial growth factor(VEGF) signaling pathway inhibitors, hypertension often leads to severe cardiovascular events, which affect the prognosis and quality of life of cancer patients seriously. However, the mechanism, pathogenesis, management and treatment of VEGF inhibitor related hypertension are mentioned rarely in current guidelines. In order to recognize the special type of hypertension more deeply, literatures were comprehended in this article.

关 键 词：高血压 肿瘤 血管内皮生长因子信号通路抑制剂 

分 类 号：R453.9[医药卫生—治疗学]